 |
7 Companies | 6 Products |
|
|
6 Products | |
29 Diseases | |
11 Trials |  |
763 News |  |
| «12...2122232425262728293031...134135» |
- | Ilaris (canakinumab) / Novartis
Journal: Interleukin-1β suppression dampens inflammatory leukocyte production and uptake in atherosclerosis. (Pubmed Central) - Oct 26, 2022
Our murine and human data reveal that anti-IL-1β treatment and NLRP3-inflammasome inhibition dampened vascular inflammation and progression of atherosclerosis through reduced blood inflammatory leucocyte (i) supply and (ii) uptake into atherosclerotic aortas providing additional mechanistic insights into links between haematopoiesis and atherogenesis, and into the beneficial effects of NLRP3-inflammasome- and IL-1β-targeted therapies.
- | Preclinical, Journal: Inhibition of miR-423-5p exerts neuroprotective effects in an experimental rat model of cerebral ischemia/reperfusion injury. (Pubmed Central) - Oct 26, 2022
In contrast, the miR-423-5p mimic yielded opposite results. In conclusion, inhibition of miR-423-5p expression could effectively attenuate ischemic stroke and might be considered a promising target for stroke.
- | Journal: Coptisine attenuates post‑infectious IBS via Nrf2‑dependent inhibition of the NLPR3 inflammasome. (Pubmed Central) - Oct 26, 2022
It is important to note that the anti‑inflammatory effects of coptisine were blocked by the Nrf2 inhibitor ML385. In summary, the present study indicated that coptisine potentially attenuated PI‑IBS in rats via Nrf2‑dependent inhibition of the NLPR3 inflammasome.
- | Journal: Ginsenoside Rh4 remodels the periphery microenvironment by targeting the brain-gut axis to alleviate depression-like behaviors. (Pubmed Central) - Oct 26, 2022
The correlation analysis indicated that the Rh4-inhibited LPS/NLRP3/caspase-1/IL-1β signaling pathway plays a key role in ameliorating depression. Therefore, this study provides valuable insights into the mode of action of Rh4 on the brain-gut axis in depression, suggesting that Rh4 may be a promising clinical drug for the treatment of depression.
- | Journal: ChREBP Deficiency Suppresses Renal Inflammation and Fibrosis Via Inhibiting NLRP3 Inflammasome Activation in Diabetic Kidney Disease. (Pubmed Central) - Oct 25, 2022
Therefore, this study provides valuable insights into the mode of action of Rh4 on the brain-gut axis in depression, suggesting that Rh4 may be a promising clinical drug for the treatment of depression. Our findings establish a critical role of ChREBP in engaging inflammation and renal fibrosis by regulating NLRP3 inflammasome activation in DKD.
- | Journal: A novel anti-atherosclerotic mechanism of quercetin: Competitive binding to KEAP1 via Arg483 to inhibit macrophage pyroptosis. (Pubmed Central) - Oct 25, 2022
Furthermore, after administration of adeno associated viral vector (AAV) with AAV-KEAP1-R483S, the anti-atherosclerotic effects of quercetin were almost abolished in ApoE mice. These findings proved quercetins suppressed macrophage pyroptosis by targeting KEAP1/NRF2 interaction, and provided reliable data on the underlying mechanism of natural antioxidants to protect against atherosclerosis.
- | Preclinical, Journal: Inhibition of Dectin-1 Alleviates Neuroinflammatory Injury by Attenuating NLRP3 Inflammasome-Mediated Pyroptosis After Intracerebral Hemorrhage in Mice: Preliminary Study Results. (Pubmed Central) - Oct 25, 2022
Mechanistically, Dectin-1 blockade inhibits NLRP3 inflammasome activation, thereby alleviating neuroinflammatory injury by attenuating NLRP3 inflammasome-mediated pyroptosis both in vivo and in vitro. Our study indicates that the inhibition of Dectin-1 alleviates neuroinflammation by attenuating NLRP3 inflammasome-mediated pyroptosis after ICH.
- | Journal: S100A9‑containing serum exosomes obtained from patients with burn injuries promote myocardial cell pyroptosis through NLRP3. (Pubmed Central) - Oct 25, 2022
Thereafter, CY-09, an NLRP3 inhibitor, was revealed to restore the increase in pyroptosis and IL-18, IL-1β, caspase-1, NLRP3 and GSDMD-N expression levels caused by recombinant S100A9 to be similar to the control. These findings suggested that burn injury-associated exosomes containing S100A9 can affect AC16 cell pyroptosis through NLRP3.
- | Journal: To Analyze the Mechanism of SalB Regulating SIRT1 to Inhibit NLRP3 and Its Ameliorative Effect on Tubulogastric Junction Tumor Lesions Complicated with Myocardial Injury. (Pubmed Central) - Oct 25, 2022
Caspase-1 and ASC protein expression suggesting that SalB may inhibit the activation of NLRP3 inflammasome induced by oxidative stress by activating SIRT1/AMPK/PGC-1α signaling pathway. This plays an antimyocardial injury effect.
- | Journal: Pachymic acid alleviates experimental pancreatic fibrosis through repressing NLRP3 inflammasome activation. (Pubmed Central) - Oct 25, 2022
More important, NLRP3 activator partially attenuated the effect of PA on inhibiting PSCs activation. Collectively, these data demonstrate that PA represses PSCs activation and pancreatic fibrosis through repressing NF-κB/NLRP3 signaling.
- NEUTROPHIL EXTRACELLULAR TRAPS (NETs) INDUCE STELLATE CELL ACTIVATION AND EXACERBATE FIBROSIS BY ALCOHOL BINGES IN MURINE NASH () - Oct 23, 2022 - Abstract #AASLD2022AASLD_1264;
We describe the first time that alcohol-induced NETs directly induce stellate cell activation, promoting liver fibrosis. Alcohol binges in a NASH model induce neutrophil activation via the NLRP3, and inhibition of NLRP3 inflammasome reduces liver damage and NET formation in combined liver insults of NASH and alcohol use.
- ALCOHOL BINGE-INDUCED EXTRACELLULAR ASC SPECKS PERPETUATE LIVER INFLAMMATION IN ALCOHOL-ASSOCIATED HEPATITIS EVEN AFTER ALCOHOL CESSATION () - Oct 23, 2022 - Abstract #AASLD2022AASLD_1071;
Our study revealed a critical role of ex-ASC in the propagation of systemic and liver inflammation in AH and demonstrated induction of ex-ASC by acute alcohol binge. We identified ex-ASC and NLRP3 as potential therapeutic targets in AH.
- | Journal: C9-ALS-Associated Proline-Arginine Dipeptide Repeat Protein Induces Activation of NLRP3 Inflammasome of HMC3 Microglia Cells by Binding of Complement Component 1 Q Subcomponent-Binding Protein (C1QBP), and Syringin Prevents This Effect. (Pubmed Central) - Oct 22, 2022
This improves the apoptosis of NSC-34 cells caused by PR-CM. This study is the first to link PR, C1QBP, and NLRP3 inflammasome activity in microglia and develop potential therapeutic strategies for syringin intervention in C9-ALS.
- | Journal: An in silico investigation on the interactions of curcumin and epigallocatechin-3-gallate with NLRP3 Inflammasome complex. (Pubmed Central) - Oct 22, 2022
The molecular and protein-protein interaction data indicated that the therapeutic effects of these two polyphenols are mediated by preventing the development of the NLRP3 complex. Proposed mechanisms to prevent the development of the NLRP3 complex by antioxidant curcumin and catechin.
- | Journal: Trehalose prevents glyphosate-induced hepatic steatosis in roosters by activating the Nrf2 pathway and inhibiting NLRP3 inflammasome activation. (Pubmed Central) - Oct 21, 2022
Additionally, Tre treatment evidently mitigated Gly-induced inflammasome response via inhibiting NLRP3 inflammasome activation. Overall, these observations provide novel insights that the protective action of Tre against Gly-induced hepatic steatosis is attributed to activation of Nrf2 pathway and inhibition of NLRP3 inflammasome activation.
- | Journal, IO biomarker: Protective effect of ginsenoside Rh2 against Toxoplasma gondii infection-induced neuronal injury through binding TgCDPK1 and NLRP3 to inhibit microglial NLRP3 inflammasome signaling pathway. (Pubmed Central) - Oct 21, 2022
Overall, these observations provide novel insights that the protective action of Tre against Gly-induced hepatic steatosis is attributed to activation of Nrf2 pathway and inhibition of NLRP3 inflammasome activation. Taken together, our results show that GRh2 has a protective effect against T. gondii infection-induced neuronal injury by binding TgCDPK1 and NLRP3 to inhibit NLRP3 inflammasome signaling pathway in microglia.
- || Review, Journal: NLRP3 inflammasomes: A potential target to improve mitochondrial biogenesis in Parkinson's disease. (Pubmed Central) - Oct 21, 2022
The current review takes a more comprehensive approach to elucidating the link between mitochondrial dysfunction and aberrant NLRP3 activation in PD. In addition, we focus on some inhibitors of NLRP3 inflammatory pathways to alleviate the progression of PD.
- | Visudyne (verteporfin) / Novartis
Preclinical, Journal: IL-37 improves mice myocardial infarction via inhibiting YAP-NLRP3 signaling mediated macrophage programming. (Pubmed Central) - Oct 21, 2022
In addition, we focus on some inhibitors of NLRP3 inflammatory pathways to alleviate the progression of PD. Our results demonstrated that IL-37 achieves a favorable therapeutical function on myocardial infarction by modulating YAP-NLRP3 mediated macrophage programming, providing a promising drug for the treatment of myocardial infarction.
- | cyclophosphamide / Generic mfg., pramipexole IR / Generic mfg.
Journal, IO biomarker: Pramipexole and Lactoferrin ameliorate Cyclophosphamide-Induced haemorrhagic cystitis via targeting Sphk1/S1P/MAPK, TLR-4/NF-κB, and NLRP3/caspase-1/IL-1β signalling pathways and modulating the Nrf2/HO-1 pathway. (Pubmed Central) - Oct 21, 2022
The current study verified the protective effect of PPX and LF against CP-induced HC by halting oxidative stress, inflammation, and apoptosis. The molecular mechanism underlying this protective effect may involve targeting the crosstalk among Sphk1/S1P/MAPK/NF-κB, TLR-4/NF-κB, and NLRP3/caspase-1/IL-1β signalling pathways and modulating the Nrf2/HO-1 signalling pathway.
- || Review, Journal: A Selective Review and Virtual Screening Analysis of Natural Product Inhibitors of the NLRP3 Inflammasome. (Pubmed Central) - Oct 21, 2022
Here, we review selected natural products reported in the literature as NLRP3 inhibitors, with a particular focus on those targeting gout. To complement this survey, we also report a virtual screen of the ZINC20 natural product database, predicting favored chemical features that can aid in the design of novel small molecule NLRP3 inhibitors.
- | Preclinical, Journal: High Endogenously Synthesized N-3 Polyunsaturated Fatty Acids in Fat-1 Mice Attenuate High-Fat Diet-Induced Insulin Resistance by Inhibiting NLRP3 Inflammasome Activation via Akt/GSK-3β/TXNIP Pathway. (Pubmed Central) - Oct 21, 2022
Our GSK-3β shRNA knockdown study further revealed that GSK-3β played a pivot role between the upstream AMPK/Akt pathway and downstream Nrf2/Trx1/TXNIP pathway. Given that NLRP3 inflammasome is implicated in the development of most inflammatory diseases, our results suggest the potential of n-3 PUFAs in the prevention or adjuvant treatment of NLRP3 inflammasome-driven diseases.
- | RRx-001 / EpicentRx
Preclinical, Journal: Superficial Venous-Associated Inflammation from Direct IV Administration of RRx-001 in Rats. (Pubmed Central) - Oct 21, 2022
The main observed toxicity was a significant inflammatory response in the vein wall, consistent with superficial venous thrombosis observed in man. Due to this development, direct IV infusion of RRx-001 is relatively contraindicated in favor of co-administration with autologous blood.
- | Journal: Investigating the NLRP3 Inflammasome and its Regulator miR-223-3p in Multiple Sclerosis and Experimental Demyelination. (Pubmed Central) - Oct 20, 2022
Finally, systemic delivery of MCC950 to mice following lysolecithin-induced demyelination resulted in a significant reduction in axonal injury within demyelinated lesions. In conclusion, we demonstrate that NLRP3 inflammasome activity by macrophages and microglia is a critical component of the inflammatory microenvironment following demyelination and represents a potential therapeutic target for inflammatory-mediated demyelinating diseases, including MS.
- | Journal: POP1 inhibits MSU-induced inflammasome activation and ameliorates gout. (Pubmed Central) - Oct 20, 2022
Strikingly, administration of an engineered cell permeable version of POP1 was able to ameliorate MSU crystal-mediated inflammation in vivo, as measured by neutrophil infiltration. Overall, we demonstrate that POP1 may play a crucial role in regulating inflammatory responses in gout.
- | GYY4137 / National University of Singapore
Journal: GYY4137 ameliorates sepsis-induced cardiomyopathy via NLRP3 pathway. (Pubmed Central) - Oct 19, 2022
We further found that the protective effects of GYY4137 were absent in Nlrp3-knockout models. GYY4137 ameliorates myocardial injury in SICM via the NLRP3 pathway by inhibiting the inflammatory response and reducing the production of myocardial ROS.
- | Journal: Inhibition of inflammasome activation via sphingolipid pathway in acute lung injury by Huanglian Jiedu decoction: An integrative pharmacology approach. (Pubmed Central) - Oct 19, 2022
HLD does have a better therapeutic effect on ALI, and its molecular mechanism is better elucidated from the whole, which is to balance lipid metabolism, energy metabolism and amino acid metabolism, and inhibit NLRP3 inflammasome activation by regulating the sphingolipid pathway. Therefore, HLD and its active components can be used to develop new therapies for ALI and provide a new model for exploring complex TCM systems for treating ALI.
- | Journal: Dehydroepiandrosterone inhibits vascular proliferation and inflammation by modulating the miR-486a-3p/NLRP3 axis. (Pubmed Central) - Oct 18, 2022
DHEA inhibited VSMCs and vascular intimal proliferation and inflammation by regulating the miR-486a-3p/NLRP3 axis. Therefore, DHEA might be a candidate cardiovascular protective agent in the future.
- | Journal: Inhibition of CEBPB Attenuates Lupus Nephritis via Regulating Pim-1 Signaling. (Pubmed Central) - Oct 18, 2022
Furthermore, the knockdown of CEBPB could inhibit NLRP3 inflammasome activation and pyroptosis via binding to Pim-1 promoter to downregulate its expression, and the overexpression of Pim-1 reversed the effects of CEBPB deficiency. The regulation of CEBPB on Pim-1 facilitated pyroptosis by activating NLRP3 inflammasome, thereby promoting the development of LN.
- | Bay11-7082 / InvivoGen
Preclinical, Journal: BAY-117082-driven NLRP3 inflammasome inhibition resolves nitro-glycerine (NTG) neuronal damage in in vivo model of migraine. (Pubmed Central) - Oct 18, 2022
Additionally, the treatment with BAY-117082 at both higher doses significantly modulated CREB/Erk/Akt pathways strictly correlated to the expression of neurotrophic factors. Taken together, obtained results confer new insight into the role of the NLRP3 inflammasome pathway in migraine pathogenesis, suggesting that BAY-117082 could be considered a novel strategy therapeutics for migraine treatment despite unconventional drug use.
- | Journal: Ursolic acid alleviates Kupffer cells pyroptosis in liver fibrosis by the NOX2/NLRP3 inflammasome signaling pathway. (Pubmed Central) - Oct 18, 2022
These results indicate that UA attenuates liver fibrosis in mice via inhibiting KC pyroptosis, which may be through the suppression of NOX2/NLRP3 inflammasome signaling pathway. It may be a new target for treating liver fibrosis and provide a new theoretical basis for the use of UA to treat liver fibrosis.
- | Preclinical, Journal: Double-negative T cells mediate M1 polarization of microglial cells via TNF-α-NLRP3 to aggravate neuroinflammation and cognitive impairment in Alzheimer's disease mice. (Pubmed Central) - Oct 15, 2022
We discovered that the proportion of DNTs increased in AD patients. DNTs secreted TNF-α to regulate the activation of NLRP3 inflammasome and the M1 polarization of microglial cells, thus promoting the central inflammatory response and aggravating the cognitive impairment in AD mice.
- | Journal: Crucial Function of Caveolin-1 in Deoxynivalenol-Induced Enterotoxicity by Activating ROS-Dependent NLRP3 Inflammasome-Mediated Pyroptosis. (Pubmed Central) - Oct 14, 2022
However, NLRP3 inhibition did not affect Cav-1 expression. In conclusion, our study demonstrated that pyroptosis may be an underlying mechanism in DON-induced intestinal injury, and Cav-1 plays a pivotal role in DON-induced pyroptosis via regulating oxidative stress, which suggests a novel strategy to overcome DON-induced enterotoxicity.
- || Review, Journal: The NLRP3 inflammasome as a new target in respiratory disorders treatment. (Pubmed Central) - Oct 14, 2022
The review presented, discusses the contribution of NLRP3 inflammasome to the development of allergic rhinitis, allergic asthma, and COPD. Moreover, the modulatory properties of probiotics as potential inhibitors of NLRP3 inflammasome are emphasised.
- Intra-Organ Cross-Talk via YB1 in the Kidney (Exhibit Hall, Orange County Convention Center, West Building) - Oct 13, 2022 - Abstract #KIDNEYWEEK2022KIDNEY_WEEK_2868;
Conclusion YB1 secreted from podocytes suppresses TLR-4- and NLRP3-mediated sterile inflammation in the tubular compartment, thus maintaining tubular physiology and kidney function. This uncovers a molecular mechanism of glomerular-tubular cross-talk required for normal renal physiology.
- CD8+CD103+ iTregs Attenuate Ischemia-Reperfusion AKI by Suppressing Pyroptosis (Exhibit Hall, Orange County Convention Center, West Building) - Oct 13, 2022 - Abstract #KIDNEYWEEK2022KIDNEY_WEEK_1926;
Our data suggests therapeutic potential of CD8+CD103+ iTreg in renal ischemia-reperfusion injury. Fig1.CD8+CD103+ iTregs protect against AKI in mice.
- NLRP3 Inflammasome Inhibition Decreases NETosis in AKI (Exhibit Hall, Orange County Convention Center, West Building) - Oct 13, 2022 - Abstract #KIDNEYWEEK2022KIDNEY_WEEK_1039;
In conclusion, we have demonstrated that NLRP3 inflammasome inhibition reduces kidney inflammation and inhibits NETosis-mediated kidney injury. The role of neutrophils as key effector cells and NLRP3 inflammasome pathway in kidney diseases warrants further investigation.
- | Preclinical, Journal: Viphyllin™, a standardized extract from black pepper seeds, mitigates intestinal inflammation, oxidative stress, and anxiety-like behavior in DSS-induced colitis mice. (Pubmed Central) - Oct 13, 2022
Further, the extract improves intestinal barrier function. In an important aspect of the study, we have provided the data on the effect of Viphyllin on neurological symptoms and brain health in colitis model mice.
- || Review, Journal: Targeting autophagy regulation in NLRP3 inflammasome-mediated lung inflammation in COVID-19. (Pubmed Central) - Oct 13, 2022
Specifically, we highlighted the therapeutic potential of autophagy activators in COVID-19 by inhibiting the NLRP3 inflammasome, thereby avoiding the cytokine storm. We hope this review provides enlightenment for the use of autophagy activators targeting the inhibition of the NLRP3 inflammasome, specifically the combinational therapy of autophagy modulators with the inhibitors of the NLRP3 inflammasome, antiviral drugs, or anti-inflammatory drugs in the fight against COVID-19.
- | Journal: MicroRNA-22 suppresses NLRP3/CASP1 inflammasome pathway-mediated proinflammatory cytokine production by targeting the HIF-1α and NLRP3 in Human dental pulp fibroblasts. (Pubmed Central) - Oct 13, 2022
MiR-22, as a synergetic negative regulator, is involved in controlling the secretion of proinflammatory cytokines mediated by the NLRP3/CASP1 inflammasome pathway by targeting NLRP3 and HIF-1α. These results provide a novel function and mechanism of miR-22-HIF-1α-NLRP3 signalling in the control of proinflammatory cytokine secretion, thus indicating a potential therapeutic strategy for future endodontic treatment.
- | Preclinical, Journal: Effective ex vivo inhibition of Cryopyrin-Associated Periodic Syndrome (CAPS)-associated mutant NLRP3 inflammasome by MCC950/CRID3. (Pubmed Central) - Oct 12, 2022
These results provide a novel function and mechanism of miR-22-HIF-1α-NLRP3 signalling in the control of proinflammatory cytokine secretion, thus indicating a potential therapeutic strategy for future endodontic treatment. No abstract available
- | Journal: CD5L attenuates allergic airway inflammation by expanding CD11c alveolar macrophages and inhibiting NLRP3 inflammasome activation via HDAC2. (Pubmed Central) - Oct 12, 2022
In addition, CD5L increased the CD5L macrophages and inhibited NLRP3 inflammasome activation by increasing HDAC2 expression in lung tissues of asthmatic mice. Hence, our study implicates that CD5L has potential usefulness for asthma treatment.
- | isoflurane / Generic mfg.
Journal: Andrographolide derivative AL-1 ameliorates LPS-induced acute lung injury by inhibiting NLRP3 inflammasome and lung permeability. (Pubmed Central) - Oct 12, 2022
Hence, our study implicates that CD5L has potential usefulness for asthma treatment. Taken together, these results demonstrated that AL-1 ameliorated pulmonary damage by inhibiting the activation of the NLRP3 inflammasome pathway and restoring TJ protein expression.
- | Journal: Schisandrol B protects against cholestatic liver injury by inhibiting pyroptosis through pregnane X receptor. (Pubmed Central) - Oct 12, 2022
The results illustrated that SolB could significantly inhibit NLRP3 inflammasome-induced canonical pyroptosis through the PXR/NF-κB/NLRP3 axis and inhibit Apaf-1 pyroptosome-induced noncanonical pyroptosis through the PXR/FoxO1/Apaf-1 axis. Collectively, this study revealed that SolB protected against CLI by inhibiting pyroptosis through PXR, providing new insights for understanding the molecular mechanism of SolB as a promising anti-cholestatic agent.
- | Journal: Prenylated notoamide-type alkaloids isolated from the fungus Aspergillus sclerotiorum and their inhibition of NLRP3 inflammasome activation and antibacterial activities. (Pubmed Central) - Oct 12, 2022
In addition, sclerotiamide L exhibited potent inhibition against pathogenic Staphylococcus aureus ATCC 29213 with MIC value of 4.0 μM and the growth of MRSA T144 and Enterococcus faecalis ATCC 29212. This study extends the chemical diversity of notoamide-type alkaloids, and provides potential anti-inflammasome and antibacterial lead compounds for further structure optimization.
- | Journal: Activating SIRT3 in peritoneal mesothelial cells alleviates postsurgical peritoneal adhesion formation by decreasing oxidative stress and inhibiting the NLRP3 inflammasome. (Pubmed Central) - Oct 12, 2022
In vitro treatment with HKL also restored mitochondrial bioenergetics and promoted mesothelial cell viability under oxidative stress conditions. Taken together, our findings show that the rescue of SIRT3 by HKL may be a new therapeutic strategy to alleviate and block postsurgical PA formation.
- | Journal: Theacrine alleviates sepsis-induced acute kidney injury by repressing the activation of NLRP3/Caspase-1 inflammasome. (Pubmed Central) - Oct 11, 2022
More important, Nigericin sodiumsalt (a NLRP3 agonist) damaged the effect of theacrine on repressing kidney injury markers (blood urea nitrogen and creatinine), pro-inflammatory cytokines (IL-18 and IL-1β), and cell apoptosis. Taken together, these results demonstrate that theacrine alleviates septic AKI, at least in part by repressing the activation of NLRP3 inflammasome.
- | Journal, IO biomarker: Cattle Encephalon Glycoside and Ignotin Attenuates Aβ1-42-Mediated Neurotoxicity by Preventing NLRP3 Inflammasome Activation and Modulating Microglial Polarization via TLR4/NF-κB Signaling Pathway. (Pubmed Central) - Oct 11, 2022
Furthermore, the roles of CEGI in inhibiting NLRP3 inflammasome activation, modulating microglia M1/M2 polarization, and increasing Aβ degrading enzyme expression were further validated in vivo using APP/PS1 mice. In conclusion, CEGI promotes Aβ degradation and protects microglia against Aβ1-42-induced neurotoxicity by preventing NLRP3 inflammasome activation and regulating M1/M2 polarization via TLR4/NF-κB pathways.
- Development and characterization of a microglia-restricted mouse model of NLRP3 driven neuroinflammation (SDCC Halls B-H) - Oct 10, 2022 - Abstract #Neuroscience2022NEUROSCIENCE_11241;
Ongoing characterization of this and similar model systems will allow for determination of cell-type specific activities of the NLRP3 inflammasome. Such insight into neuroinflammatory mechanisms will improve our understanding of NLRP3 biology, impacting the detection and treatment of the many diseases in which NLRP3 has been identified to play a role while providing a platform for testing novel drugs targeting the NLRP3 inflammasome.
- Withdrawn (SDCC Halls B-H) - Oct 10, 2022 - Abstract #Neuroscience2022NEUROSCIENCE_11159;
Such insight into neuroinflammatory mechanisms will improve our understanding of NLRP3 biology, impacting the detection and treatment of the many diseases in which NLRP3 has been identified to play a role while providing a platform for testing novel drugs targeting the NLRP3 inflammasome. Grant Support: NIH grant AG058673
- Bay-117082-driven nlrp3 inflammasome inhibition resolves nitro-glycerine neuronal damage in in vivo model of migraine (SDCC Halls B-H) - Oct 10, 2022 - Abstract #Neuroscience2022NEUROSCIENCE_11157;
Additionally, the treatment with BAY-117082 at both higher doses significantly modulated CREB/Erk/Akt pathways strictly correlated to the modulation of neurotrophic factors. Taken together, obtained results confer new insight into the role of the NLRP3 inflammasome pathway in migraine pathogenesis, suggesting that BAY-117082 could be considered a novel strategy therapeutics for migraine treatment despite unconventional drug use.